Document Detail

Emollient ointment for preventing infection in preterm infants.
MedLine Citation:
PMID:  10796254     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: This section is under preparation and will be included in the next issue.
OBJECTIVES: To assess the effect of prophylactic application of emollient ointment in preterm infants.
SEARCH STRATEGY: Searches were made of the Oxford Database of Perinatal Trials, Medline (MeSH terms: ointment; limits: age groups, newborn infant; publication types, clinical trial), previous reviews including cross references, abstracts, conference and symposia proceedings, expert informants, and journal handsearching in the English language.
SELECTION CRITERIA: Randomized controlled trials which compared the effect of prophylactic application of emollient ointment to routine care or as needed topical therapy in preterm infants are included in this review.
DATA COLLECTION AND ANALYSIS: Data regarding clinical outcomes including transepidermal water loss, skin condition, fluid intake, suspect infection and proven nosocomial infection were excerpted from the reports of the clinical trials by the reviewers. Data analysis was done in accordance with the standards of the Cochrane Neonatal Review Group.
MAIN RESULTS: Two randomized trials which compared prophylactic application of ointment to routine skin care or as needed topical ointment therapy were identified. Lane (1993) noted improved skin condition in infants receiving topical application of emollient ointment. In the study of Nopper and coworkers (1996), prophylactic application of ointment significantly decreased transepidermal water loss during the first six hours after initial application. Skin condition was noted to be improved during the first 1-2 weeks. Surveillance cultures demonstrated less bacterial colonization during the two week study. A significant decrease in suspect and proven infection was noted. Fewer infants were evaluated for sepsis among the group who received prophylactic application of ointment (relative risk 0. 50, 95% CI 0.27, 0.93; risk difference -0.30, 95% CI -0.54, -0.06). Both studies reported on the incidence of proven nosocomial infection. A trend towards a decrease in the risk of proven nosocomial infection was noted in infants who received prophylactic application of emollient ointment (typical relative risk 0.29, 95% CI 0.07, 1.16, typical risk difference -0.13, 95% CI -0.25, -0.01).
REVIEWER'S CONCLUSIONS: In two small studies, prophylactic application of emollient ointment decreased transepidermal water loss, decreased the severity of dermatitis, and decreased the risk of suspect sepsis and proven sepsis. Further clinical studies are warranted to validate these results.
R F Soll; W H Edwards
Related Documents :
9031954 - Predictive value of doppler umbilical artery velocimetry in a low risk population with ...
21145674 - Is routine torch screening and urine cmv culture warranted in small for gestational age...
15266494 - Intramuscular penicillin for the prevention of early onset group b streptococcal infect...
15040564 - Anaemia in pregnancy and infant mortality in tanzania.
306224 - Effect of storage and heat on antimicrobial proteins in human milk.
10021714 - Characteristics of the new milks for infants: fatty acids, nucleotides, selenium.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  The Cochrane database of systematic reviews     Volume:  -     ISSN:  1469-493X     ISO Abbreviation:  Cochrane Database Syst Rev     Publication Date:  2000  
Date Detail:
Created Date:  2000-07-06     Completed Date:  2000-07-06     Revised Date:  2013-06-28    
Medline Journal Info:
Nlm Unique ID:  100909747     Medline TA:  Cochrane Database Syst Rev     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  CD001150     Citation Subset:  IM    
Department of Pediatrics, University of Vermont College of Medicine, A-121 Medical Alumni Building, Burlington, Vermont 05405-0068, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cross Infection / prevention & control*
Dermatitis / prevention & control*
Emollients / therapeutic use*
Infant, Newborn
Infant, Premature
Infant, Premature, Diseases / prevention & control*
Ointments / therapeutic use
Reg. No./Substance:
0/Emollients; 0/Ointments
Update In:
Cochrane Database Syst Rev. 2004;(1):CD001150   [PMID:  14973963 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Furosemide for symptomatic patent ductus arteriosus in indomethacin-treated infants.
Next Document:  Types of intra-muscular opioids for maternal pain relief in labour.